The staging system proposed for neuroblastoma by Evans et al. divided patients with disseminated disease into two subgroups termed stages IV and IV-S, S for 'special'.1 The IV-S patients had primary tumours* that were stage I or II and involvement of the liver, skin, bone marrow (or a combination of these), without roentgenographic evidence of bone metastases. It was found that such children had a better survival rate than patients with stage IV-77 % compared with 6 %.2 Subsequently it was shown that most patients were infants in the first months of life, that the majority survived with minimal treatment, and that a large percentage had evidence of spontaneous regression.3 All three papers dealt with retrospective analyses of patients collected over a period of two decades. Since the concept was first suggested that there existed a special disease pattern * The term primary tumour is used to describe a neoplasm in one of the common sites of origin for neuroblastoma-that is, the adrenal gland, the sympathetic ganglia, the organs of Zuckerkandi, etc. 'Distant disease' or similar terms are used to designate neuroblastoma in other sites. It 3 , and 1 died before treatment could be given; the tumour will be removed electively in the remaining 2 some time in the future.
Disease in the liver was irradiated in 11, and chemotherapy was given to 6. Six patients were given combined chemo-and irradiation therapy, and 6 received no treatment. The dose to the liver ranged from 200 to 1200 rad with a median of 450. Of the 6 patients treated with chemotherapy, cyclophosphamide was used in 4, cyclophosphamide with vincristine in 1, and cyclophosphamide, vincristine, plus imidazole carboxamide in 1. The duration of chemotherapy varied between 1 month and 1 year. Half of the patients with marrow disease received chemotherapy and half had no treatment. The skin lesions were excised in 2 patients, treated with chemotherapy in 2, and 4 had no treatment. The patient with a presumed pancreatic nodule and the pleural foci responded to two 10-day courses of cyclophosphamide, the serosal lesion was not treated.
Nine patients had no treatment other than removal of the primary tumour, and all survived. These 9 had disease in the liver only (3), liver, marrow, and serosa (l), liver and marrow (1), liver and skin (2), and skin only (2). There were 6 additional patients who showed evidence of spontaneous regression of at least one tumour site, all 6 had disease in the marrow and 1 had skin lesions too. In all, these 15 patients had 19 sites of disease which were untreated and regressed spontaneously ( Table 2 ).
The 31 patients of this report have been followed up for between 2 
Discussion
Early reports of stage IV-S disease were subject to criticism because each was a retrospective review of patients seen over a period of decades. Unconscious bias could colour such analyses in that only the Do infants with stage IV-S neuroblastoma need treatment? 273 patients who survived or had unusually protracted courses were identified, and those who died early were grouped with the stage IV children and thus were masked from the reviewer. These problems were largely avoided in these 31 patients. Information on them was collected for a relatively brief period by one observer and the IV-S designation was agreed at the time of diagnosis before the long-term clinical course had become manifest.
Another doubt expressed concerning the 'natural history' of such patients is that the age rather than the pattern of disease per se is the more important factor. Certainly infants with stage IV disease fare better than older children with similarly advanced disease. This is documented by the data reported by Breslow Whether the disseminated foci in these patients represent metatastic involvement or multicentric primary tumours (a special form of neurocristopathy) is unknown and is discussed at greater length elsewhere.5
Not all the IV-S patients fare well. Nine of the 31 patients here reported had continued growth or spread of disease after initial treatment and 4 died. Six of the 9 were 1 month of age at diagnosis, and the very young infant seems vulnerable to the mechanical complications caused by a greatly enlarged liver. Such complications are raised diaphragms leading to respiratory problems, compression of the inferior vena cava and renal vasculature with resultant kidney failure, gastric compression or hepatic dysfunction with secondary haemorrhagic problems resulting from compression of liver lobules by tumour growth. It is striking that none of the children developed icterus until late in the course of the disease despite massive hepatomegaly often being present at diagnosis or soon after. It is also clear that these children differ from the usual picture of late stage IV disease where emaciation, bone pain, proptosis, and other tumour masses become evident at scattered sites. The 4 children who died from hepatic involvement were vigorously treated to reverse the mechanical problems described above, but nonetheless died from the complication ofhepatic tumour size or its treatment rather than from the spread ofcancer. All 4 who died did so in the first 2 months. It appears characteristic of the syndrome that the tumour grows rapidly in some patients before it undergoes spontaneous regression. If tumour growth can be arrested during this initial phase late recurrences leading to death are rare.
The 5 patients with progressive disease that did respond to treatment were all 1-month old when first seen and were apparently still in the first phase of the disease (before the natural regression). Two each developed a single skull lesion below a tumour in the scalp; both responded to treatment.
The most striking aspect of this group of patients however, is not that 9 of 31 had some form of progressive disease, but that 15 had spontaneous regression of neuroblastoma at at least one site, most often marrow (8) or liver (6). The marrow infiltration was not heavy in the 6 preparations reviewed but were undoubtedly tumour clumps; they were not activated lymphocytes which must be differentiated from isolated tumour cells. 6 So far in this group of patients there have been no late relapses, although many have been followed only for a short period.* Such late relapses have been reported, both recurrent primary disease and bone metastases ;7-9 this is a rare phenomenon and we have not met it.
Some conclusions regarding treatment can be drawn from this review. Treatment 
